Denmark-based diabetes and obesity giant Novo Nordisk (NOV: N) says it plans to invest 8.5 billion Danish kroner ($1.2 billion) to establish a completely new production facility in Odense, Denmark.
The investment marks the first time in this century that Novo Nordisk breaks ground in Denmark by establishing a new production site. It adds to the companies list of recent investments in new production facilities, included earlier this month $420 million at its control laboratory in Hillerød, Denmark, and $4.1 billion to build a second fill and finishing manufacturing facility in Clayton, North Carolina, USA, announced in June.
The new Odense site will feature a state-of-the-art finished production facility and warehouse spanning over 40,000 m2. Designed to be modular and flexible, it will accommodate multiple product types within rare disease, such as hemophilia, both now and in the future.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze